Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study

医学 内科学 放化疗 头颈部 肿瘤科 基底细胞 顺铂 头颈部癌 头颈部鳞状细胞癌 放射治疗 化疗 外科 总体生存率
作者
Xu-Shan Sun,Yungan Tao,Christophe Le Tourneau,Y. Pointreau,Christian Sire,Marie‐Christine Kaminsky,Alexandre Coutté,M. Alfonsi,Pierre Boisselier,Laurent Martin,J. Miroir,Jean‐François Ramée,Jean‐Pierre Delord,Florian Clatot,Frédéric Rolland,Julie Villa,Nicolas Magné,Olgun Eliçin,Elisabeta Gherga,F. Nguyen,C. Lafond,G. Béra,Valentin Calugaru,Lionnel Geoffrois,Bruno Chauffert,Angela Zubel,Claudio Zanna,S. Brienza,Philippa Crompton,Elisabeth Rouits,Kathrin Gollmer,Sergio Szyldergemajn,Jean Bourhis
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:21 (9): 1173-1187 被引量:100
标识
DOI:10.1016/s1470-2045(20)30327-2
摘要

Background Debio 1143 is an orally available antagonist of inhibitor of apoptosis proteins with the potential to enhance the antitumour activity of cisplatin and radiotherapy. The radiosensitising effect of Debio 1143 is mediated through caspase activation and TNF, IFNγ, CD8 T cell-dependent pathways. We aimed to investigate the efficacy and safety of Debio 1143 in combination with standard chemoradiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck. Methods This double-blind, multicentre, randomised, phase 2 study by the French Head and Neck Radiotherapy Oncology Group (GORTEC) was run at 19 hospitals in France and Switzerland. Eligible patients were aged 18–75 years with locoregionally advanced, squamous cell carcinoma of the head and neck (characterised as non-metastatic, measurable stage III, IVa, or IVb [limited to T ≥2, N0–3, and M0] disease), Eastern Cooperative Oncology Group performance status of 0 or 1, a history of heavy tobacco smoking (>10 pack-years) with no previous or current treatment for invasive head and neck cancer, and no previous treatment with inhibitor of apoptosis protein antagonists. Patients were randomly assigned (1:1) to receive oral Debio 1143 (200 mg per day on days 1–14 of 21-day cycles, for three cycles) or oral placebo (20 mg/mL, administered at the same dosing schedule) using a stochastic minimisation technique according to node involvement and primary tumour site, and HPV-16 status in patients with an oropharyngeal primary tumour site. All patients received standard high-dose cisplatin chemoradiotherapy. The primary endpoint was the proportion of patients with locoregional control 18 months after chemoradiotherapy, analysed in the intention-to-treat population (primary analysis), and repeated in the per-protocol population. Responses were assessed according to Response Evaluation Criteria in Solid Tumors (version 1.1). This trial is registered with ClinicalTrials.gov, NCT02022098, and is still active but not recruiting. Findings Between Jan 25, 2016, and April 24, 2017, 48 patients were randomly assigned to the Debio 1143 group and 48 to the placebo group (one patient in the placebo group did not receive the study drug and was not included in the safety analysis). Median duration of follow-up was 25·0 months (IQR 19·6–29·4) in the Debio 1143 group and 24·2 months (6·6–26·8) in the placebo group. Locoregional control 18 months after chemoradiotherapy was achieved in 26 (54%; 95% CI 39–69) of 48 patients in the Debio 1143 group versus 16 (33%; 20–48) of 48 patients in the placebo group (odds ratio 2·69 [95% CI 1·13–6·42], p=0·026). Grade 3 or worse adverse events were reported in 41 (85%) of 48 patients in the Debio 1143 group and in 41 (87%) of 47 patients in the placebo group. The most common grade 3–4 adverse events were dysphagia (in 24 [50%] patients in the Debio 1143 group vs ten [21%] in the placebo group), mucositis (in 15 [31%] vs ten [21%]), and anaemia (in 17 [35%] vs 11 [23%]). Serious treatment-emergent adverse events were recorded in 30 (63%) of 48 patients in the Debio 1143 group and 28 (60%) of 47 in the placebo group. In the placebo group, two (4%) deaths were due to adverse events (one multiple organ failure and one asphyxia; neither was considered to be related to treatment). No deaths due to adverse events occurred in the Debio 1143 group. Interpretation To our knowledge, this is the first treatment regimen to achieve superior efficacy in this disease setting against a high-dose cisplatin chemoradiotherapy comparator in a randomised trial. These findings suggest that inhibition of inhibitor of apoptosis proteins is a novel and promising approach in this poor prognostic population and warrant confirmation in a phase 3 study with the aim of expanding the therapeutic options for these patients. Funding Debiopharm.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
1秒前
无风海发布了新的文献求助10
2秒前
4秒前
海上森林的一只猫完成签到 ,获得积分10
4秒前
大胆问丝发布了新的文献求助10
8秒前
SciGPT应助Wait采纳,获得10
9秒前
Hong完成签到 ,获得积分10
9秒前
TLB完成签到,获得积分10
12秒前
16秒前
16秒前
冰凉应助初之采纳,获得20
19秒前
迷路博完成签到,获得积分10
20秒前
20秒前
NexusExplorer应助周周采纳,获得10
24秒前
24秒前
白榆完成签到 ,获得积分10
24秒前
25秒前
26秒前
26秒前
nimo发布了新的文献求助10
28秒前
Sid应助难过梦竹采纳,获得40
28秒前
29秒前
改论文不看剧应助竼竼采纳,获得10
30秒前
31秒前
无骨鸡爪不长胖完成签到,获得积分10
31秒前
31秒前
轩墨完成签到,获得积分10
31秒前
英俊的铭应助an采纳,获得10
33秒前
橘橙色发布了新的文献求助10
33秒前
半糖发布了新的文献求助10
33秒前
小白菜发布了新的文献求助10
34秒前
35秒前
周周发布了新的文献求助10
36秒前
汉堡包应助王柯采纳,获得10
41秒前
轩墨发布了新的文献求助10
41秒前
爆米花应助半糖采纳,获得10
42秒前
英姑应助孙成成采纳,获得10
42秒前
44秒前
小白菜完成签到,获得积分10
45秒前
领导范儿应助nimo采纳,获得10
47秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975516
求助须知:如何正确求助?哪些是违规求助? 3519930
关于积分的说明 11200130
捐赠科研通 3256278
什么是DOI,文献DOI怎么找? 1798183
邀请新用户注册赠送积分活动 877425
科研通“疑难数据库(出版商)”最低求助积分说明 806320